+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Carboxes 1018899-04-1
1018899-04-1,MFCD22493506
Catalog No.:AA0005RF

1018899-04-1 | (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol

Pack Size
Purity
Availability
Price(USD)
Quantity
  
10mg
98%
in stock  
$6.00   $4.00
- +
25mg
98%
in stock  
$8.00   $6.00
- +
50mg
98%
in stock  
$11.00   $8.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA0005RF
Chemical Name:
(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol
CAS Number:
1018899-04-1
Molecular Formula:
C21H25ClO5S
Molecular Weight:
424.9382
MDL Number:
MFCD22493506
SMILES:
CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](SC)[C@H]([C@@H]([C@H]1O)O)O
Properties
Computed Properties
 
Complexity:
476  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
5  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
6  
XLogP3:
3.2  

Downstream Synthesis Route

[1]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-WO2008/42688,2008,A2Locationinpatent:Page/Pagecolumn38

[1]CurrentPatentAssignee:SHENZHENDONGYANGGUANGINDUSTRIALDEVELOPMENTCOLTD-CN106892948,2017,ALocationinpatent:Paragraph0313;0315;0316

[2]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-WO2008/42688,2008,A2Locationinpatent:Page/Pagecolumn38-39

1018899-04-1   
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylsulfonyl)-tetrahydro-2H-pyran-3,4,5-triol 

[1]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-WO2008/42688,2008,A2Locationinpatent:Page/Pagecolumn39

[1]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-WO2021/19507,2021,A1Locationinpatent:Page/Pagecolumn9-12

[2]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-US2009/30198,2009,A1Locationinpatent:Page/Pagecolumn11

[3]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-EP2332947,2011,A1Locationinpatent:Page/Pagecolumn10

[4]Zhao,MatthewM.;Zhang,Haiming;Iimura,Shinya;Bednarz,MarkS.;Song,Qiu-Ling;Lim,Ngiap-Kie;Yan,Jie;Wu,Wenxue;Dai,Kuangchu;Gu,Xiaodong;Wang,Youchu[OrganicProcessResearchandDevelopment,2020,vol.24,#11,p.2689-2701]

[5]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-US2009/30198,2009,A1Locationinpatent:Page/Pagecolumn11

[6]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-US2010/16422,2010,A1Locationinpatent:Page/Pagecolumn7

[7]CurrentPatentAssignee:OCEANUNIVERSITYOFCHINA-CN108912080,2018,ALocationinpatent:Paragraph0092-0097

[8]Chen,Pengwei;Ding,Han;Li,Ming;Liu,Li;Lv,Zhihua;Sun,Qikai;Wang,Peng;Wang,Xianyang;Zhou,Xin[AngewandteChemie-InternationalEdition,2020,vol.59,#10,p.4138-4144][Angew.Chem.,2020,vol.132,#10,p.4167-4173,7]

[9]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-US2009/30198,2009,A1Locationinpatent:Page/Pagecolumn12

[10]CurrentPatentAssignee:SUZHOUPENGXUPHARMATECHCO.,LTD.-CN110818722,2020,ALocationinpatent:Paragraph0044

[11]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2018/67805,2018,A1Locationinpatent:Paragraph0096

[1]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-EP2332947,2011,A1

[2]CurrentPatentAssignee:LEXICONPHARMACEUTICALSINC-EP2661256,2018,B1

Literature

Title: Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Journal: Diabetes & vascular disease research 20150301

Title: LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Journal: Clinical pharmacology and therapeutics 20120801

Title: Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.

Title: Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1018899-04-1
1018899-03-0

1018899-03-0
Building Blocks
More >
Tags:1018899-04-1 Molecular Formula|1018899-04-1 MDL|1018899-04-1 SMILES|1018899-04-1 (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol